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Background: Many types of tumors are organized in a hierarchy of heterogeneous cell populations with different
molecular signature. Such heterogeneity may be associated with different responsiveness to microenvironment
stimuli. In the present study, the effects of lipopolysaccharide (LPS) and lipoteichoic acid (LTA), as well-known
mediators of inflammation, on cancerous behavior of three prostate tumor cells, LNCaP, PC3 and DU145, were
investigated.
Methods: Expression of TLR1-10, CD14 and MyD88 transcripts was investigated by RT-PCR. Protein expression of
TLR2 and 4 was scrutinized by flow cytometry, immunofluorescent staining and Western blotting. Experiments were
set up to assess the effects of LPS and LTA at different concentrations and times on cell proliferation, extracellular
matrix invasion, adhesion and cytokine production.
Results: We showed that prostate cancer cell lines differentially express TLR1-10, MyD88 and CD14 transcripts.
DU145 failed to express TLR4 gene. Positively-identified TLR2 protein in all prostate cancer cells and TLR4 protein in
PC3 and LNCaP by Western blotting was not accompanied by cell surface expression, as judged by flow cytometry.
Immunofluorescent staining clearly demonstrated predominantly perinuclear localization of TLR2 and TLR4. LTA
activation of all prostate cancer cells significantly increased cell proliferation. Regardless of lacking TLR4, DU145 cells
proliferated in response to LPS treatment. While LPS caused increased invasiveness of LNCaP, invasive capacity of
PC3 was significantly reduced after LPS or LTA stimulation. Stimulation of all prostate tumor cells with LTA was
associated with increased cell adhesion and IL-8 production. IL-6 production, however, was differentially regulated
by LPS stimulation in prostate tumor cells.
Conclusion: The data shows that cancer cells originated from the same histologically origin exhibit heterogeneous
response to the same TLR ligand. Therefore, a thorough and comprehensive judgment on how and to what extent
a particular cancer is affected by TLR agonist could not be inferred by studying an individual cell line.
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Immune recognition of microorganisms is carried out
by a set of receptors collectively referred to as pattern
recognition receptors (PRR). These receptors are expressed
by wide variety of immune cells and, as an essential part
of innate immunity, are involved in immediate and direct
recognition of molecular determinants specific to certain
classes of pathogens [1]. TLRs are more recent class of
PRR which comprise a family of at least ten molecules
expressed in wide range of organisms from Drosophila to
higher mammals [2-4]. Each individual TLR is believed to
recognize specific classes of microbial determinants. TLRs
2, 3, 4, 5, 7 and 9 sense bacterial lipoproteins, double-
stranded RNA/poly (I:C), lipopolysaccharides, flagellin,
single stranded RNA and CPG-containing DNA, respect-
ively [5-14]. Most TLRs including TLR2 and 4 signal
through a common adaptor protein, myeloid differenti-
ation primary response gene 88 (MyD88). Following TLR
ligation, recruitment of MyD88 takes place which in turn
associates with the intracellular domain of the TLR [15-18]
leading to subsequent downstream activation of the nu-
clear factor, NF-kB, signaling pathway. The latter is re-
sponsible for the initiation of pro-inflammatory responses
characterized by the production of a vast array of chemo-
kines and cytokines and in some cell populations by cell
proliferation, as well [19]. Although most of the studies on
TLRs published so far have focused on their expression
and function in immune cells, there are accumulating set
of evidence indicating that other cell types including epi-
thelial cells and cancer cells of different origin also express
TLRs [20,21].
It is widely accepted that chronic inflammation is
among the main triggers of tumorigenesis [22] and in
this regard cancer cells may benefit from inflammatory
process through expression of TLRs leading to further
propagation and development of chemoresistance. There
are plenty of reports providing compelling evidence sup-
porting the role of inflammatory process induced by
bacterial and viral components in carcinogenesis or al-
teration of invasive behavior of previously-established
tumors [23-25].
Attempting to explore the TLR biology in cancer, sev-
eral research projects have been carried out with cell
lines affiliated to the solid tumors of different origin in-
cluding colon, breast, prostate, melanoma, lung, larynx,
neuroblastoma, ovary and cervix, to list a few [26-33]. In
most settings, however, the expression pattern has been
surveyed at the gene level only and data on functional
expression of TLRs on cancer cells is rather elusive with
contradictory results. According to some reports, TLR
engagement leads to production of pro-inflammatory
factors such as IL-12, IL-6 and nitric oxide by tumor
cells and results in their resistance to cytotoxcicity and
apoptosis, increased invasiveness, chemoresistance andtumor growth [24,28,34-39]. In contrast, some tumors
are unresponsive to TLR ligands regardless of posses-
sing all the downstream molecules required for TLR
signaling [27,40].
In developed countries, prostate cancer is the most
common cancer in men, and it ranks third overall in
terms of mortality [41]. A great body of evidence sup-
ports the hypothesis that environmental factors such as
chronic inflammation and infection are important for
development of prostate cancer [42]. It has been shown
that LNCaP prostate cancer cells, when exposed to the
conditioned media of LPS-activated THP-1 macrophage
cells, produce pro-inflammatory cytokines and upregu-
late markers associated with cell immune evasion and
tumor progression [43]. Nonetheless, there is a great de-
bate on pro- and anti-tumoral activity of different TLRs
in prostate cancer [44]. Based on the fact that many
types of tumors are organized in a hierarchy of heteroge-
neous cell populations, we hypothesized that such
skepticism may stem from different behavior of prostate
cancer cells with different molecular signatures. There-
fore we examined and compared expression of TLR1-10,
MyD88 and CD14 and functional responsiveness to
TLR-2 and 4 ligands in well-established prostate cancer
cell lines.
Results
Expression of TLRs, CD14 and MyD88 transcripts in
prostate cancer cell lines
Expression of TLR1-10, MyD88 and CD14 in prostate
cancer cells, LNCaP, PC3 and DU145, was studied by
RT-PCR. Results are shown in Figure 1A. PC3 and
DU145 expressed CD14 above detection limit, while
LNCaP failed to express this marker. TLR1-10 and
MyD88 were differentially expressed by these cell lines
with different densities. Of the TLR genes examined,
LNCaP failed to express detectable levels of TLR7 and 8
and exhibited very low level expression of TLR2, while
DU145 expressed all TLRs except TLR4, TLR7 and 9.
Except TLR7, PC3 expressed all TLR transcripts. All cell
lines expressed MyD88.
Expression of TLR2 and TLR4 proteins in prostate cancer
cell lines
In order to investigate TLR2 and TLR4 protein expression
and their subcellular localizations, three protein readout
systems were employed. In Western blot analysis, specific
bands of about 100 and 95 KDs were detected in PBMC
(as positive control) for TLR2 and TLR4, respectively. In
line with PCR results, cell lines with positive gene expres-
sion also expressed corresponding proteins (Figure 1B).
DU145 failed to express TLR4 protein. Surface expression
of TLR2 and TLR4 proteins in prostate cell lines was
examined by flow cytometric analysis. Monocyte gate of
Figure 1 Expression of TLRs in human prostate cancer cell
lines. A: RT-PCR showing expression of TLR1-10, MyD88 and CD14
transcripts. RT-PCR was performed according to the protocol
described in Materials and methods. PBMC served as positive
control. Amplification of Beta-actin in the same samples was used as
loading control. No amplification controls (NC)(no reverse transcriptase
added) were included as negative controls in all PCR programs.
B: Western blot analysis of TLR2 and TLR4 expression. Positive
sample and loading controls were included as RT-PCR experiments.
Lanes in which primary antibodies were substituted by non-immune
sera served as negative controls (NC). Similar results were observed
in three independent experiments.
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showed that, none of the cell lines expressed TLR2 or
TLR4 on their surface. Indeed, no detectable levels of
surface CD14 was found in prostate cancer lines. Mono-
cytes as positive control expressed high levels of TLR2,
TLR4 and CD14 on their surface (Figure 2A). To test
whether surface expression of TLR2 and 4 is affected by
LPS, LTA or IL-1, they were pretreated with a mixture
of LPS + IL-1 or LTA + IL-1 depending on expression of
TLR2 and TLR4 transcripts. The results clearly showed
that such treatments could not up regulate surface ex-
pression of TLR2 and 4 in prostate cancer cell lines
(Figure 2B). Based on the results of Western blot andflow cytometric analyses, we were then about to localize
TLR2 and TLR4 expression in prostate cancer cells. In
immunofluorescent staining, TLR2 and TLR4 were
mainly localized to the peri-nuclear region of the cells
(Figure 2C).Effects of TLR ligands on prostate cancer cell proliferation
Uncontrolled cell proliferation is without any doubt a
hallmark of cancerous cells and in this regard micro-
environment in which the cells reside has fundamental
effect on this behavior. TLR expression by these cells
may influence their proliferation rate through receptor-
ligand engagement. To this end, the effect of TLR4 and
TLR2 ligands, LPS and LTA, on proliferation of prostate
cancer cell lines was examined. To do this, cells were
treated by a broad concentration range of aforesaid
ligands and their proliferation was measured by XTT
assay in reference to unstimulated cells. Although, DU145
cells failed to express TLR4 transcript, they also stimulated
by LPS to see whether presence of specific ligands are
necessary to induce functional proliferative response.
The result showed that different prostate cell lines had
completely different proliferative response to TLR2 and
4 ligands (Figure 3). Although DU145 did not express
cognate receptor for LPS, their proliferation capacity
was significantly increased in response to different con-
centrations of LPS (p < 0.001) (Figure 3A). Although we
used highly pure LPS, to rule out the possibility of con-
tamination of LPS with other TLRs ligands we per-
formed cell proliferation assay in DU145 cells using
Polymyxin B to neutralize LPS. The results of such experi-
ment clearly showed that LPS neutralization lowered
proliferative capacity of DU145 cells to the baseline
level (p < 0.001). Also, omission of exogenous CD14 sig-
nificantly abolished LPS-induced proliferation of this
cell line (p < 0.05) (Figure 3B).
LPS treatment did not alter proliferation of LNCaP
or PC3 regardless of TLR4 expression (Figure 3A). LTA
treatment at all concentrations significantly increased
proliferation of LNCaP, DU145 and PC3 cells (p < 0.05
or p < 0.001 depending on cell type and LTA concen-
tration) (Figure 3C). Interestingly, as kinetic study
demonstrated, responder cells also showed consider-
ably varying response to the different concentrations of
LPS or LTA. In the case of DU145, low concentrations
of LPS were more effective in triggering proliferative re-
sponse compared to very high concentration (1000 ng/ml).
The same pattern was also seen when PC3 cell line was
treated with LTA. Considering different basal level pro-
liferation in cell lines tested, stimulation index (SI) was
calculated and compared. In response to LTA treatment,
DU145 had the highest SI in all concentrations exam-
ined (data not shown).
Figure 2 Flow cytometric analysis of TLR2 and TLR4 expression in human prostate cancer cell lines. A: Basal levels of TLR2, TLR4 and
CD14 expression was assessed using specific antibodies (white areas) or isotype controls (gray areas). Monocyte gate of PBMC served as positive
control. B: Cells were stimulated with a combination of LPS + IL-1 or LTA + IL-1 and expression of TLR2 and TLR4 was evaluated as above. The
diagrams are representative of at least three independent experiments. C: Immunofluorescent localization of TLR2 and TL4 in prostate cancer cell
lines. MACS-purified human monocytes and HL-60 cell line served as positive control for TLR2 and TLR4 expression, respectively. Scale bare:
50 μm.
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by prostate cancer cells
Inflammatory cytokines such as IL-6, IL-8 and TNFα
have major role in tumor biology and with this notion in
mind; production of these cytokines by prostate cancer
cell lines was studied at basal level and after stimulation
with LPS and LTA. The results revealed that different
prostate cell lines have different capacity to produce
baseline levels of these cytokines and more interestingly
respond in totally different manner to LPS or LTA
stimulation. All cell lines failed to produce detectable
levels of TNFα either in baseline levels or after stimula-
tion with LPS or LTA. DU145 produced significantly
higher basal levels of IL-6 compared to other cell lines
(p < 0.001). Stimulation with LPS or LTA resulted in sig-
nificantly higher levels of IL-6 production in DU145
cells (p < 0.001, p < 0.01), while such treatments had no
considerable effect on IL-6 production by other two cell
lines (Figure 4A). In a similar way to IL-6, highest
amounts of IL-8 were produced by DU145 (p < 0.001).
LPS treatment caused significant reduction of IL-8 pro-
duction by DU145 (p < 0.05), while the opposite was
true for LTA treatment (p < 0.01). LTA or LPS treatment
caused significant increase in IL-8 production by LNCaP(p < 0.001, p < 0.01). PC3 failed to produce IL-8 at basal
levels or after stimulation with LPS. LTA treatment,
however, caused minimal detectable levels of IL-8 pro-
duction by this cell line (Figure 4B).
Effects of TLR2 and TL4 ligation on invasiveness of
prostate cancer cells
Invasion is a process in which the cancer cells degrade
extracellular matrix and invade to the surrounding tissue.
Invasion is profoundly under the influence of micro-
environment. In this regard Gram positive and negative
bacteria may affect the invasive potential of tumors
through stimulation of TLRs. With this notion, effect of
LPS and LTA on invasive behavior of prostate cancer
cell lines was investigated. The results of this experi-
ment revealed that, basal invasion capacity of PC3 was
significantly higher compared to other cell lines (p < 0.001)
(Figure 5A). In PC3 cells, LPS treatment significantly
reduced the capacity of the cells to invade (p < 0.001).
The results of LTA stimulation was the same as LPS
stimulation. LPS and LTA did not affect the invasion
capacity of DU145. In LNCaP cells LPS but not LTA
stimulation caused significant increase in invasion cap-
acity (p < 0.001) (Figure 5B).
Figure 3 Effects of TLR activation on proliferation of human prostate cancer cell lines. The effects of LPS (A) and LTA (C) on proliferation
of prostate cancer cell lines were examined. Cells were treated with a wide concentration range of LPS or LTA and their proliferation was
measured by XTT assay in reference to vehicle-treated cells. To rule out the possibility of contamination of LPS with other TLR ligands, LPS was
neutralized by Polymyxin B and the level proliferation in DU145 cells was assessed either in the presence or absence of soluble CD14 (B). Each
bar represents the mean ± SD of three independent experiments and each test was done in triplicate. In each cell line, the data were compared
to vehicle-treated (control) cells. c: p < 0.001, a: p < 0.05.
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adhesion
In the next experiment, effect of LPS and LTA on adhe-
sion of prostate cell lines to extra cellular matrix was sur-
veyed. Different time points (50, 100, 150 and 200 min)
was examined to find the optimal time point in which
prostate cancer cell lines had the highest adhesion. All cell
lines exhibited highest adhesiveness in 150 min, afterward
cells gradually detached from the plate. In all time inter-
vals, PC3 had the highest adhesive capacity compared toother cell lines. Stimulation of LNCaP with LTA but not
LPS caused statistically significant increase in cell adhe-
sion (p < 0.01) (Figure 6A). LTA also increased adhesive
properties of DU145 (Figure 6B). Stimulation of PC3 with
LTA and LPS caused statistically significant increase in cell
adhesion (Figure 6C). To compare adhesive potential of
different cell lines in response to LPS or LTA stimulation,
the ratio of optical density of stimulated to non-stimulated
state was calculated for each cell line and compared.
The results of such comparison revealed that LTA has
Figure 4 Effects of TLR2 and TL4 ligation on cytokine
production by human prostate cancer cell lines. Prostate cancer
cells were treated with LPS or LTA and concentrations of IL-6 (A)
and IL-8 (B) were measured in culture supernatants by ELISA. Each
bar represents the mean ± SD of three independent experiments
and each test was done in triplicate. In each cell line, the data were
compared to vehicle-treated (control) cells. c: p < 0.001, b: p < 0.01,
a: p < 0.05.
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of PC3 compared to the other cell lines (p < 0.001) (data
not shown).
Discussion
Inflammation has long been known to be associated with
the development of cancer. Multiple mechanisms are in-
volved in inflammation-induced carcinogenesis; among
others are anti-apoptotic effects of nuclear factor-κB
(NF-κB), induction of oxidative damage to DNA and the
induction of the tissue repair response [45]. Studies in
human and animal models imply that inflammation might
have a role in prostate cancer development and progres-
sion from organ-confined to metastatic disease [46-49].
Since prostate has proximity to the surfaces which could
potentially be colonized by Gram negative and Gram
positive bacteria, it is conceivable to hypothesize that
infectious agents produce inflammation may be important
factor in triggering prostate cancer. Whether infections,particularly ascending urethral infections, are respon-
sible for prostate carcinogenesis remains an intriguing
but unresolved question [50,51]. The potential role of
genitourinary infection in the etiology of prostate can-
cer has been extensively investigated for 30 years. Des-
pite the variable study designs and methodological
approaches, there is no conclusive evidence for a direct
link between infection and prostate cancer [52]. In
most cases of prostatitis, no causal infectious agent can
be identified making it difficult to link infection with
prostate cancer in epidemiologic studies. However, an
increased risk of prostate cancer in patients with sexu-
ally transmitted infections suggests that inflammation,
rather than infection, initiates prostatic carcinogenesis
[48,53,54]. In line with this possibility, intake of anti-
oxidants or non-steroidal anti-inflammatory drugs
has been associated with a decreased risk of prostate
cancer [55,56].
Identifying the triggering events of inflammatory re-
sponses is one of the major challenges in understanding
the connection between inflammation and cancer. Infec-
tion is the best characterized triggering factor of inflam-
mation and TLRs are among the well-characterized
receptors that initiate infection-mediated inflammatory
responses [57]. Here we unrevealed some new aspects of
functional consequences of TLR2 and 4 activation in
LNCaP, DU145, and PC3 cells, which display low, mod-
erate, and high metastatic potential, respectively [58].
We showed that different prostate cancer cell lines have
different TLR expression profile, indicating their poten-
tial different capability for microenvironment sensing.
Notably, TLR7 which sense synthetic compounds like
Resiquimod (R-848) with potent anti-tumor activity was
absent in all prostate cancer cell lines. Interestingly and
consistent with the assumption that cancer cells may
benefit from TLR signaling, the most aggressive prostate
cell line, PC3, expressed the most comprehensive TLR
sets. All cell lines expressed detectable levels of MyD88
implying that they might use MyD88-dependent TLR
signaling pathways. Since in some cases there was no
amplification in RT-PCR, possible polymorphisms in the
annealing area of the primer pairs with no amplification
in at least one cell line were checked in Ensemble gene
browser (www.ensembl.org). Although there were some
SNPs in the annealing area of the primers, such SNPs
are unlikely to interfere with RT-PCR because: a) They
were located in the middle part of primer binding sites
and not in the 3’ region. Mismatches at the 3’ terminus
of a primer-template duplex are more detrimental to
PCR than internal mismatches. b) All primers we used,
successfully amplified the gene of interest in at least two
(and in most instances three) out of four cell types we
investigated. c) The annealing area of the some genes
which were amplified in all cell types (eg: TLR10) also
Figure 5 Effects of TLR2 and TL4 ligation on invasive capacity of human prostate cancer cell lines. A: Each cell line was treated with LPS
or LTA during invasion assay. Invading cells were stained, photographed (A), counted at 200 × in at least 50 fields and averaged (B). Each bar
represents the mean ± SD of three independent experiments. In each cell line, the data were compared to vehicle-treated (control) cells. c: p < 0.001.
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affect the results of RT-PCR. In spite of this, the possi-
bility that some cell lines express certain isoform of a
given transcript that is not recognized by the primers
used in this study could not be ruled out.
Although the expression profile of multiple TLRs in
cancer cells from different histologically origin has been
investigated [59], few data are available on functional ex-
pression of TLR2 and TLR4 in prostate cancer cells.
Here we showed that LNCaP and PC3 cells, although
harbour TLR2 and TLR4 proteins, do not express these
receptors on their surface. Although TLR2 and TLR4 is
usually expressed on the cell surface of immune cells,
there are a number of reports on intracellular expres-
sion of these receptors in various cell types such as cor-
onary artery endothelial cells [60], intestinal epithelial
cells [61] and neuroblastoma cell line [27]. Interestingly,
LPS-induced TLR4 signaling in intestinal epithelial cellsoccurs at the site of the Golgi apparatus and LPS-
mediated cellular activation requires ligand internaliza-
tion that occurs via a lipid raft dependent formation of
clathrin-coated pits and intracellular transport to the
Golgi compartment [61]. In the same way, TLR2 and its
ligand, LTA, are internalized to Golgi apparatus and this
process seems to be lipid raft-dependent [62]. Our re-
sults supported this set of data by showing that TLR2
and TLR4 were mainly localized to the peri-nuclear
region, corresponding to Golgi apparatus. Interestingly,
Takeyama et al. [63] reported surface expression of
TLR2 in PC3 cells which is in contrary with what we re-
ported here. They used flow cytometry for assessment
of surface expression of TLR2, while in our system flow
cytometry results were confirmed with immunofluores-
cent staining.
It has been reported that expression levels of TLRs, par-
ticularly TLR2 and TLR4, in immune and non-immune
Figure 6 Effects of TLR2 and TL4 ligation on adhesion capacity
of human prostate cancer cell lines. LNCaP (A), DU145 (B) and
PC3 (C) cells were treated with LPS or LTA and their adhesion
capacity of cells was assesses in fibronectin-coated plates at different
time intervals by colorimetric assay. Each bar represents the mean ± SD
of three independent experiments and each test was done in triplicate.
In each cell line, the data were compared to vehicle-treated (control)
cells. c: p < 0.001, b: p < 0.01, a: p < 0.05.
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inflammatory cytokines. Our results showed that surface
expression of TLR2 and TLR4 in prostate cancer cells is
not affected by such treatments suggesting that TLR2 and
TLR4 expressions are differentially regulated in a cell-
specific fashion. We showed that, in spite of the absence
of surface expression of TLR2 and TLR4, prostate tumorcells are responsive to LPS and LTA implying that activa-
tion is mediated through ligand internalization. Such in-
ternalization processes of TLR ligands have been reported
in epithelial cells [64] and may represent a natural regula-
tory step in the process of LPS or LTA-mediated activation
of prostate epithelial cells to avoid overwhelming pro-
inflammatory stimulation by the ascending infections.
For two reasons, expression of a given TLR on cancer
cells could not be always considered as an advantageous
natural selection process. First, expression of TLRs on
cancer cells may not be necessarily associated with func-
tional responses to their cognate ligands [65], and the
second is the conflicting roles that have been attributed
to TLR ligation in human cancers [26,32,66] including
prostate carcinoma [63]. Due to chronic tissue damage
with subsequent repair processes that could evolve in
uncontrolled cell proliferation, infection-induced inflam-
matory responses can potentially enhance tumorigenesis.
In parallel, tissue damage that usually occurred during
cancer growth can elicit TLR-dependent generation of
inflammatory products associated with recruitment of
leukocytes with tumor promoting potentials [67]. On the
contrary, engagement of TLRs with their ligands has
been shown to induce apoptosis of tumor cells or to
cause tumor regression indirectly by recruiting NK and
cytotoxic T cells [68]. In this context, we evaluated func-
tional consequences of TLR2 and TLR4-mediated acti-
vation in prostate cancer cells including proliferation,
cell attachment, invasion and pro-inflammatory cytokine
production.
We showed that different prostate cancer cell lines
have different responsiveness to activation by LPS or
LTA. While LPS induced significant increase of cell pro-
liferation only in DU145 cells, LTA at all concentrations
exhibited proliferative effect on all prostate cells tested.
LPS also increased cell invasion in LNCaP, whereas both
LPS and LTA reduced invasiveness of PC3, the most in-
vasive prostate cancer cell line. The precise mechanism
of this differential behavior of prostate cancer cells is not
clear at the moment. The prostate cancer cells investi-
gated here are distinct prostate cell lines, with differing
origin (LNCaP from a lymph node; PC3 from bone; and
DU145 from brain [69], invasiveness and androgen sen-
sitivity. More importantly, they have unique expression
pattern of genes, cell surface markers, transcriptional and
signaling regulatory network and proteome and secretome
which may be related to the different microenvironment
they isolated [70-72]. For instance, LNCaP cells maintains
various metabolic pathways, while, PC3 cells are charac-
terized by their unique expression of cytoskeleton-related
genes [71] implying that they might behave differentially
in response to different stimuli. Equally important, LNCaP,
DU145 and PC3 prostate carcinoma cell lines exhibit
differential basal NF-κB activation levels. The highest
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cells [64], consistent with our results showing that this cell
type produced significantly higher basal and LTA- or LPS-
induced levels of pro-inflammatory cytokine, IL-6, com-
pared to the other two cells. Surprisingly, the functional
responsiveness to LPS in DU145 cells occurred in the ab-
sence of TLR4 transcript implying that compensatory
pathways are responsible for capture and internalization
of LPS in this cell line. It has been shown that TLR2 serves
as primary receptor for Gram-positive bacteria and
their cell wall components, whereas TLR4 as the pri-
mary LPS receptor. Subsequently, it was evident that
human HEK293 cells co-transfected with TLR2, CD14
and myeloid differentiation protein 2 (MD-2), became
highly responsive to all LPS preparations even at 0.1-
1 ng/ml. Therefore, MD-2 enables very sensitive TLR2/
CD14-mediated recognition of LPS [73]. Also, in an
elegant work conducted by Yang et al., it was reported
that TLR2 is activated by LPS in a response that is en-
hanced by CD14 [74]. We showed that neutralization
of LPS by polymyxin B abrogated proliferative effect of
LPS on DU145 cells to the baseline level indicating that
LPS could actually increase proliferative capacity of cells
lacking TLR4. Interestingly, omission of exogenous CD14
significantly abolished cell proliferation induced by LPS
suggesting synergistic effect of CD14 and LPS on TLR4−
DU145 cells proliferation. Taken together, it seems that
although TLR4 is a prototype receptor for LPS, its ab-
sence could be compensated by other relevant receptors
of TLR family.
Prostate cancer cell lines also exhibited differential basal
adhesiveness to solid matrix. Their adhesive capacity was
also differed considerably in response to LPS and LTA
treatments. The highly metastatic PC3 cell line attached
more rapidly than all other cell types then entered a phase
of spontaneous cell detachment about three hours after
initiation of cell culture. Cytoskeletal architecture plays an
important role in regulating cell adhesion and PC3 cells
are characterized by their unique cytoskeleton-related
genes compared to the other prostate cancer cell lines
[71]. Importantly, increased adhesion capacity of PC3 cell
line following LPS or LTA stimulation was accompanied
by its reduced invasion potential. In line with this finding,
it has been reported that there is a positive correlation be-
tween the invasion into extracellular matrix and lack of
cell adhesion [75]. In contrast to PC3, LPS treatment in
LNCaP cells had positive effect on cell adhesion implying
that cells from the histologically same origin differentially
regulate their adhesion molecules in response to PAMPs.
Promotion of cell adhesion following LPS activation has
also been reported in colorectal cancer cell lines [38].
From the data presented here some important points
can be inferred: First, TLR activation in a particular can-
cer cell line could be associated with different and insome instances contrasting consequences. In this context,
focusing on only one behavior of cancer cells following
TLR stimulation, as done by some researchers, may be
misleading and overall effects on different fundamental
aspects of cancer cell behavior should be considered for
correct interpretation. Second, cancer cells originated
from the same histologically origin exhibit heteroge-
neous response to the same TLR ligand. Therefore, a
thorough and comprehensive judgment on how and to
what extent a particular cancer is affected by TLR agon-
ist could not be inferred by studying an individual cell
line. And finally, based on the information provided in
the literature and the data presented here, different can-
cer types may positively or negatively regulated by TLR
activation, a conclusion that is supported by extensive
debate on the role of TLR in cancer [68].
Materials and methods
Cell lines and culture
Human prostate cell lines, PC3, DU145 and LNCaP
were purchased from national cell bank of Iran. PBMC,
MACS-purified monocytes or HL-60 cell line (national
cell bank of Iran) were used as positive control of TLR
expression, where appropriate. Cells were cultured in
RPMI 1640 supplemented with 10% FBS (GIBCO, USA),
penicillin and streptomycine at 37°C and 5% CO2. In
order to avoid endotoxin contamination and mainten-
ance of their original characteristics, cells were passaged
with disposable plastic wares not more than 4 times be-
fore their cryopreservation.
RNA Extraction and Complementary DNA (cDNA)
Synthesis
Total RNA from cell homogenates was extracted by stand-
ard protocol. Briefly, chloroform was added to and mixed
with RNA-Bee (Biosite, Sweden) solution containing suffi-
cient number of cells, total RNA was collected from liquid
supernatant and precipitated by two steps of alcohol pre-
cipitation. Extracted RNA was dissolved in 20–50 μL of
sterile water. In each run of RNA extraction, quality of
RNA was evaluated by gel electrophoresis. Ten microliters
of total RNA from each cell line was heated to 65°C and
immediately cooled on ice. A volume corresponding to
2 μg of RNA was added to the cDNA Mix including 5×
buffer (Fermentase, Vilnius, Lithuania), 2 m MdNTP
mix (Roche, Penzberg, Germany), 2 mM Random hex-
amer (Cybergene, Stockholm, Sweden), and 20 U⁄mL RT
M-MuLV (Fermentase) in a final volume of 10 μL. The
mixture was then incubated in 42°C for 60 min. The
cDNA was then kept at −20°C.
Reverse transcriptase polymerase chain reaction (RT-PCR)
PCR was carried out according to the protocol we pub-
lished recently with some modifications [76]. In brief,
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http://www.cancerci.com/content/14/1/541 μL cDNA and 1 μL of each pair of primers (adapted
from [77] except TLR4, MyD88, CD14 and β-actin
which are designed in our laboratory) (Table 1), equivalent
to the final concentrations of 0.4 pM for β-actin (as load-
ing control) and 0.2 pM for TLR1-10, MyD88 and CD14
were added to 12.5 μl of ready to use master mix (Ampli-
qon, Denmark). After initial heating at 94°C for 3 minutes,
PCR was performed 30 (for β-actin) or 35 cycles (for
TLR1-10, MyD88 and CD14) with annealing temperatures
listed in Table 1. For all PCR programs, denaturation and
extension temperatures of 94°C and 72°C, respectively
were applied for 30 seconds. Final extension for 7 minutes
was performed for all amplifications. PCR systems devoid
of template cDNA and no amplification controls (no
reverse transcriptase added) were included as negative
controls.Cell treatment
Each cell line was treated with pre-determined concen-
trations of LPS (Cat No: L4391 from Sigma, USA) and
LTA (Cat No: L2515 from Sigma) in a specified time
period. In cell lines with no expression of surface CD14,
LPS treatments were accompanied by treatment with
1 ng/ml recombinant CD14 (R&D, USA). Concentration
of LPS and LTA and treatment period varied depending
on the experiment. Control wells were treated with ve-
hicle and the same concentration of soluble CD14. In
some experiments, CD14 was omitted to investigate the
synergistic effect of this molecule on LPS-induced cell
proliferation. To rule out the possibility of contamination
of LPS with other TLRs ligands, LPS was neutralized using
Polymyxin B (Sigma, USA) and the level of cell prolifera-
tion in DU145 cells was then quantified.Table 1 Sequence, amplicon size and annealing temperatures













βactine GTGGGGCGCCCCAGGCACCA CTCCTTAATGTCACInvasion assay
6-well matrigel invasion chambers (BD, USA) were rehy-
drated by warm DMEM in cell culture incubator, at 37°C,
5% CO2 for 2 h. After removing the medium, 2 ml of
DMEM containing 5% FBS and 2 ml of cell suspension
containing 1.25 × 105 cells/ml in DMEM were added to
the wells and upper inserts, respectively. Each cell line
was treated with 100 ng/ml of LPS, 1 μg/ml of LTA or
vehicle during the culture period. Non-invading cells
were then removed from the upper surface of the mem-
branes by scrubbing with cotton-tipped swabs two times
followed by washing with warm culture medium. The
cells on the lower surface of the membranes were fixed
with ice cold methanol and stained with 1% toluidine
blue each for 4 min followed by air drying. Membranes
were removed from the insert housing by scalpel and
mounted on the microscope slides. Invading cells were
counted at 200 × in at least 50 fields and averaged.
Adhesion assay
Effect of LPS and LTA on attachment capacity of pros-
tate cancer cell lines was examined by cell attachment
assay using fibronectin-coated 96-well attachment plates
(BD). One day before assay, cells were passaged in loga-
rithmic phase and after overnight culture were treated
with 100 ng/ml LPS or 1 μg/ml LTA for 4 h. Cell sus-
pensions were prepared and the cell count was adjusted
to 2.5 × 105/ml in DMEM. One hundred μl of cell sus-
pension was added to each well in triplicate and plates
were incubated with lid off at 37°C, 5% CO2 for 50, 100,
150 and 200 min. After gentle washing with warm PBS
to remove non-adherent cells, adherent cells were fixed
with 2% (v/v) formaldehyde for 10 min. After being
washed three times with water, cells were stained withof primers used in this study
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http://www.cancerci.com/content/14/1/540.1% crystal violet for 30 min. Wells were washed as
above and dye was solubilized in 10% (v/v) acetic acid
on orbital shaker at 150 rpm for 5 min. The extent of
adhesion was evaluated by measuring the optical density
at 595 nm.
Cytokine assay
Cells suspended in RPMI containing 10% FBS were
seeded in 96 well tissue culture plates at 50000 cell/well.
After overnight culture, cells were treated with 100 ng/ml
LPS or 1 μg/ml LTA for 48 h. Some cells remained un-
treated as control. Supernatants were collected, centri-
fuged and stored in -70°C for cytokine assay. Amounts
of TNF-α, IL-8 (BD) and IL-6 (R&D, USA) in culture
supernatant were measured according to the protocol
provided by the manufacturer.
SDS-PAGE and Western blotting
SDS gel electrophoresis and Western blotting were per-
formed according to the protocol we published else-
where [78]. Briefly, 2.0 ×107 cells were homogenized in
1 ml complete RIPA Lysis Buffer System (Santa Cruz,
USA) containing, 1.941 mM PMSF, 0.97 mM sodium
orthovanadate and 1% (v/v) protease inhibitor cocktail
and the protein content of cleared supernatants was de-
termined by BCA protein assay (Pierce Biotechnology,
USA). The samples were then separated on 10% SDS
gel under reducing condition and transferred to the
PVDF membrane. The membranes were blocked with
5% non-fat dry milk and probed with 1:100 dilution of
goat anti-human TLR2 (Santa Cruz, USA) or 1 μg/mL
goat anti-human TLR4 (R&D, USA) for 2 h. Membranes
were consequently incubated with peroxidase-conjugated
rabbit anti-goat secondary antibody (Avicenna research
Institute, Iran) at a dilution of 1:10000. For protein loading
control, membranes were stripped and re-probed with
rabbit anti-human beta actin antibody (Sigma, USA) and
peroxidase-conjugated sheep anti-rabbit Ig (Avicenna
Research Institute) as above. The resulting signals were
visualized using ECL Detection kit (GE Healthcare, UK)
according to the manufacturer’s instruction. In negative
control lanes, the primary antibodies were substituted
by pre-immune goat serum.
Flow cytometric analysis of TLR2 and TLR4 expression
In order to determine surface expression of TLR2 and
TLR4, flow cytometric analyses were performed. All in-
cubations were performed on ice. For TLR2 staining, the
cells were incubated with Alexa fluor 488 conjugated
anti-TLR2 antibody (BD) for 30 min. For TLR4 staining,
a two-step staining protocol using biotin-conjugated
anti-TLR4 (BD) and PE-Cy5.5 conjugated streptavidin
(Invitrogen, USA) was utilized. In negative reagent control
tubes, isotype matched irrelevant antibodies were usedinstead of the primaries. In some settings cells were
treated with 50 ng/ml IL-1 and 100 ng/ml LPS or 1 μg/ml
LTA for 24 h before flow cytometric analysis. Signals were
analyzed by Partec flow cytometer (Partec, Germany). As
positive control, monocyte gate of PBMC was analyzed in
parallel.
Immunofluorescent staining
Immunofluorescent staining of TLR2 and TLR4 was per-
formed as described elsewhere [79]. Briefly, cells were
cytospinned and fixed with either ice cold acetone (for
TLR2) or natural buffered formalin (for TLR4). Primary
antibodies [goat anti-TLR2 (Santa cruze), 1:100 for over-
night or goat anti-TLR4 mouse (R&D), 10 μg/mL for 3 h]
were added followed by 1:50 dilution of FITC-labeled
rabbit anti-goat Ig (Avicenna Research Institute) for
60 min. Cells were then washed and counterstained
with 4'-6-diamidino-2-phenylindole (DAPI) (BD). Fluor-
escent signals were visualized and photographed by a
BX51 Olympus microscope equipped with DP71 CCD
camera.
Assessment of cell proliferation
Cell suspension in phenol red-free DMEM (Sigma, USA)
supplemented with 10% FBS was plated in 96 well flat-
bottom tissue culture plates (BD) at a pre-determined
concentration of 104 cell/well in a final volume of 100 μl.
The optimal cell density and incubation time were de-
termined for each cell line by titration and kinetic ex-
periments where optimal conditions yielded the optical
densities (OD) between 0.3-0.8 in the logarithmic por-
tion of the standard curve. After that, 100 μl of phenol
red-free DMEM containing LPS or LTA (final concen-
trations: 1–1000 ng/ml) was added to the test wells in
triplicate, while control wells received the same volume
of vehicle. After 48 hours, XTT was prepared at 1 mg/ml
in pre-warmed (37°C) serum and phenol red-free DMEM.
PMS was prepared at 5 mM (1.53 mg/ml) in PBS. Fresh
XTT and PMS were mixed together at the appropriate
concentrations. For a 0.025 mM PMS-XTT solution, 25 μl
of the stock 5 mM PMS was added per 5 ml of XTT
(1 mg/ml). 50 μl of this mixture (final concentration,
50 μg of XTT and 0.38 μg of PMS per well) was added to
each well and the plates were incubated at 37°C, 5% CO2
for 4 hours. Thereafter, the OD values were read at
450 nm. For each cell line, the mean OD value of wells
without cells was subtracted from that of test and control
wells to calculate net OD value of each well.
Statistical analysis
The SPSS version 13.0 (SPSS Inc., Chicago, IL) was used
for all analyses. In all quantitative experiments the re-
sults represent data of three independent experiments
and each test was done in triplicate. In case of invasion
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http://www.cancerci.com/content/14/1/54assay which was performed in three independent exper-
iments but not as triplicate in each individual test, 50
fields were enumerated for each well. So, for statistical
analysis, one-way analysis of variance (ANOVA) was
used for group wise comparisons, followed by the appro-
priate post hoc tests (Dunnett’s). Figures are represented
by Graphpad Prism Version 3 (GraphPad Software,
SanDiego, CA). Results were considered significant at
p < 0.05.
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